Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta …

M Khunger, S Rakshit, V Pasupuleti, AV Hernandez… - Chest, 2017 - Elsevier
Background Programmed death 1 (PD-1) programmed death-ligand 1 (PD-L1) inhibitors
show significant clinical activity in non-small cell lung carcinoma (NSCLC). However, they
are often associated with potentially fatal immune-mediated pneumonitis. Preliminary
reports of trials suggest a difference in the rate of pneumonitis with PD-1 and PD-L1
inhibitors. We sought to determine the overall incidence of pneumonitis and differences
according to type of inhibitors and prior chemotherapy use. Methods MEDLINE, Embase …